Drugs

, Volume 54, Issue 6, pp 801–840 | Cite as

The Role of Plant-Derived Drugs and Herbal Medicines in Healthcare

Review Article

Summary

Many of our present medicines are derived directly or indirectly from higher plants. While several classic plant drugs have lost much ground to synthetic competitors, others have gained a new investigational or therapeutical status in recent years. In addition, a number of novel plant-derived substances have entered into Western drug markets. Clinical plant-based research has made particularly rewarding progress in the important fields of anticancer (e.g. taxoids and camptothecins) and antimalarial (e.g. artemisinin compounds) therapies. In addition to purified plant-derived drugs, there is an enormous market for crude herbal medicines.

Natural product research can often be guided by ethnopharmacological knowledge, and it can make substantial contributions to drug innovation by providing novel chemical structures and/or mechanisms of action. In the end, however, both plant-derived drugs and crude herbal medicines have to take the same pharmaco-economic hurdle that has become important for new synthetic pharmaceuticals.

Keywords

Paclitaxel Malaria Atopic Eczema Artemisinin Familial Mediterranean Fever 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lewis WH, Elvin-Lewis MPF. Medical botany. Plants affecting man’s health. New York: John Wiley and Sons, 1977Google Scholar
  2. 2.
    Beal JL, Reinhard E, editors. Natural products as medicinal agents. Stuttgart: Hippokrates Verlag, 1981Google Scholar
  3. 3.
    Sneader W. Drug discovery: the evolution of modern medicines. Chichester: John Wiley and Sons, 1985Google Scholar
  4. 4.
    Robbers JE, Speedie MK, Tyler VE. Pharmacognosy and pharmacobiotechnology. Baltimore: Williams and Wilkins, 1996Google Scholar
  5. 5.
    Kinghorn AD, Balandrin MP, editors. Human medicinal agents from plants: ACS Symposium Series 534. Washington, DC: American Chemical Society, 1993Google Scholar
  6. 6.
    Evans WC, editor. Trease and Evans’ Pharmacognosy. 14th ed. London: WB Saunders Company Ltd, 1996Google Scholar
  7. 7.
    Reynolds JEF, Parfitt K, Parsons AV, et al., editors. Martindale: the extra pharmacopoeia. 31st ed. London: Pharmaceutical Press, 1996Google Scholar
  8. 8.
    Cragg GM, Newman DJ, Snader KM. Natural products in drug discovery and development. J Nat Prod 1997; 60: 52–60PubMedGoogle Scholar
  9. 9.
    Reynolds JEF, Parfitt K, Parsons AV, et al., editors. Martindale: the extra pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993Google Scholar
  10. 10.
    Collier JG, Robinson BE, Vane JR. Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide (B.P.P.9a or SQ 20,881) which inhibits converting enzyme. Lancet 1973: I: 72–4Google Scholar
  11. 11.
    Larach JH. Concept of anti-renin system therapy: historic perspective. Am J Med 1984; 77 Suppl. 2A: 1–6Google Scholar
  12. 12.
    Bird C. Medicines from the rainforest. New Sci 1991 Aug 17; 34–9Google Scholar
  13. 13.
    Plotkin MJ. Conservation, ethnobotany, and the search for new jungle medicines: pharmacognosy comes of age … again. Pharmacotherapy 1988; 8: 257–62PubMedGoogle Scholar
  14. 14.
    Van der Heide H, Tinke JL. Facts and figures 1996. The Hague: Foundation for Pharmaceutical Statistics, 1996Google Scholar
  15. 15.
    O’Neill MJ, Lewis JA. The renaissance of plant research in the pharmaceutical industry. In: Kinghorn AD, Balandrin MF, editors. Human medicinal agents from plants: ACS Symposium Series 534. Washington, DC: American Chemical Society, 1993: 48–55Google Scholar
  16. 16.
    Farnsworth NR, Akerele O, Bingel AS, et al. Medicinal plants in therapy. Bull WHO 1985; 63: 965–81PubMedGoogle Scholar
  17. 17.
    Soejarto DD, Farnsworth NR. Tropical rain forests: potential source of new drugs? Perspect Biol Med 1989; 32: 244–56PubMedGoogle Scholar
  18. 18.
    De Smet PAGM. Health risks of herbal remedies. Drug Saf 1995; 13: 81–93PubMedGoogle Scholar
  19. 19.
    Synthetic THC approved by FDA. Clin Pharm 1985; 4: 479, 482Google Scholar
  20. 20.
    WHO model prescribing information: drugs used in parasitic diseases. Geneva: World Health Organization, 1995Google Scholar
  21. 21.
    Drugs for parasitic infections. Med Lett Drugs Ther 1995; 37: 99–108Google Scholar
  22. 22.
    International consensus report on the diagnosis and management of asthma. Clin Exp Allergy 1992; 22Suppl. 1: 1–68Google Scholar
  23. 23.
    British Thoracic Society. Guidelines for the management of asthma: a summary. BMJ 1993; 306: 776–82Google Scholar
  24. 24.
    De Meijer PHM. Digitalis in congestive heart failure. Neth J Med 1994; 45: 225–32PubMedGoogle Scholar
  25. 25.
    De Smet PAGM. Current health status of betacarotene supplementation. Int Pharm J 1996; 10: 213–4Google Scholar
  26. 26.
    Sawynok J. Pharmacological rationale for the clinical use of caffeine. Drugs 1995; 49: 37–50PubMedGoogle Scholar
  27. 27.
    Scanlon JEM, Chin KC, Morgan MEI, et al. Caffeine or theophylline for neonatal apnoea? Arch Dis Child 1992; 67: 425–8PubMedGoogle Scholar
  28. 28.
    Rumsfield JA, West DP. Topical capsaicin in dermatologic and peripheral pain disorders. Drug Intell Clin Pharm 1991; 25: 381–7Google Scholar
  29. 29.
    Capsaicin — a topical analgesic. Med Lett Drugs Ther 1992; 34: 62–3Google Scholar
  30. 30.
    Clarke IM. Peppering pain [commentary]. Lancet 1993; 342: 1130PubMedGoogle Scholar
  31. 31.
    Watson CPN. Topical capsaicin as an adjuvant analgesic. J Pain Symptom Manage 1994; 9: 425–33PubMedGoogle Scholar
  32. 32.
    Zhang WY, Li Wan Po A. The effectiveness of topically applied capsaicin: a meta-analysis. Eur J Clin Pharmacol 1994; 46: 517–22PubMedGoogle Scholar
  33. 33.
    Emmerson BT. The management of gout. N Engl J Med 1996; 334: 445–51PubMedGoogle Scholar
  34. 34.
    Emmerson BT. The management of gout [letter]. N Engl J Med 1996; 334: 1543–4Google Scholar
  35. 35.
    Douglas WW, Ryu JH, Bjoraker JA, et al. Colchicine versus prednisone as treatment of usual interstitial pneumonia. Mayo Clin Proc 1997; 72: 201–9PubMedGoogle Scholar
  36. 36.
    Skinner M, Anderson JJ, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996; 100: 290–8PubMedGoogle Scholar
  37. 37.
    Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202–7PubMedGoogle Scholar
  38. 38.
    Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet 1989; I: 1093–6Google Scholar
  39. 39.
    Vuoristo M, Färkkilä M, Karvonen A-L, et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology 1995; 108: 1470–8PubMedGoogle Scholar
  40. 40.
    Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996; 335: 1570–80PubMedGoogle Scholar
  41. 41.
    Zemer D, Livneh A, Danon YL, et al. Long-term colchicine treatment in children with familial mediterranean fever. Arthritis Rheum 1991; 34: 973–7PubMedGoogle Scholar
  42. 42.
    Livneh A, Zemer D, Langevitz P, et al. Colchicine treatment of AA amyloidosis of familial mediterranean fever: an analysis of factors affecting outcome. Arthritis Rheum 1994; 37: 1804–11PubMedGoogle Scholar
  43. 43.
    Drenth JPH. Efficacy of colchicine in familial mediterranean fever is well established [letter]. BMJ 1996; 313: 233PubMedGoogle Scholar
  44. 44.
    Raghu G. Idiopathic pulmonary fibrosis: a need for treatment with drugs other than corticosteroids. A role for antifibrotic agents? Mayo Clin Proc 1997; 72: 285–7PubMedGoogle Scholar
  45. 45.
    Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993; 329: 1–7PubMedGoogle Scholar
  46. 46.
    Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525–33Google Scholar
  47. 47.
    Harvey AL. The pharmacology of galanthamine and its analogues. Pharmacol Ther 1995; 68: 113–28PubMedGoogle Scholar
  48. 48.
    Galanthamine: the new treatment of choice in Alzheimer’s disease? Inpharma 1995; 1002: 3–5Google Scholar
  49. 49.
    Bores GM, Huger FP, Petko W, et al. Pharmacological evaluation of novel Alzheimer’s disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 1996; 277: 728–38PubMedGoogle Scholar
  50. 50.
    Snorrason E, Stefansson JG. Galanthamine hydrobromide in mania [letter]. Lancet 1991; 337: 557PubMedGoogle Scholar
  51. 51.
    Tamaoki J, Chiyotani A, Sakai A, et al. Effect of menthol vapour on airway hyperresponsiveness in patients with mild asthma. Respir Med 1995; 89: 503–4PubMedGoogle Scholar
  52. 52.
    British Photodermatology Group. British Photodermatology Group guidelines for PUVA. Br J Dermatol 1994; 130: 246–55Google Scholar
  53. 53.
    Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995; 332: 581–8PubMedGoogle Scholar
  54. 54.
    Herrmann JJ, Roenigk HH, Hurria A, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 1995; 33: 234–42PubMedGoogle Scholar
  55. 55.
    Lundquist G, Forsgren H, Gajecki M, et al. Photochemotherapy of oral lichen planus: a controlled study. Oral Surg Oral Med Oral Pathol 1995; 79: 554–8Google Scholar
  56. 56.
    Vogelsang GB, Wolff D, Altomonte V, et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant 1996; 17: 6: 1061–7PubMedGoogle Scholar
  57. 57.
    Laing TJ, Ike RW, Griffiths CEM, et al. A pilot study of the effect of oral 8-methoxypsoralen and intraarticular ultraviolet light on rheumatoid synovitis. J Rheumatol 1995: 22: 29–33PubMedGoogle Scholar
  58. 58.
    Stern RS, Nichols KT, Väkevä LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med 1997; 336: 1041–5PubMedGoogle Scholar
  59. 59.
    Wolff K. Should PUVA-therapy be abandoned? [editorial] N Engl J Med 1997; 336: 1090–1PubMedGoogle Scholar
  60. 60.
    Thirwell MP, Sloan PA, Maroun JA, et al. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer 1989; 63: 2275–83Google Scholar
  61. 61.
    Expert Working Group of the European Association for Palliative Care. Morphine in cancer pain: modes of administration. BMJ 1996; 312: 823–6Google Scholar
  62. 62.
    Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 1996; 335: 1124–32PubMedGoogle Scholar
  63. 63.
    Rhodes J, Thomas G. Nicotine treatment in ulcerative colitis. Drugs 1995; 49: 157–60PubMedGoogle Scholar
  64. 64.
    Pullan RD, Rhodes J, Ganesh S, et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994; 330: 811–5PubMedGoogle Scholar
  65. 65.
    Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 364–71PubMedGoogle Scholar
  66. 66.
    Thomas GA, Rhodes J, Mani V, et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995; 332: 988–92PubMedGoogle Scholar
  67. 67.
    Newhouse PA, Hughes JR. The role of nicotine and nicotinic mechanisms in neuropsychiatric disease. Br J Addict 1991; 86: 521–6PubMedGoogle Scholar
  68. 68.
    Henahan S. Benefits with nicotine in cognitive disorders — not just a pipe dream. Inpharma 1995 Apr; 29: 3–4Google Scholar
  69. 69.
    De Smet PAGM. Larrea tridentata. In: De Smet PAGM, Keller K, Hänsel R, et al., editors. Adverse effects of herbal drugs. Vol. 2. Heidelberg: Springer-Verlag, 1993: 231–40Google Scholar
  70. 70.
    Budavari S, editor. The Merck index: an encyclopedia of chemicals, drugs, and biologicals. 12th ed. Whitehouse Station: Merck and Co., Inc., 1996Google Scholar
  71. 71.
    Masoprocol for multiple actinic keratoses. Med Lett Drugs Ther 1993; 35: 97Google Scholar
  72. 72.
    Olsen EA, Abernethy ML, Kulp-Shorten C, et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol 1991; 24: 738–43PubMedGoogle Scholar
  73. 73.
    Epstein E. Warning! Masoprocol is a potent sensitizer [letter]. J Am Acad Dermatol 1994; 31: 295–6PubMedGoogle Scholar
  74. 74.
    Cooper JK. Drug treatment of Alzheimer’s disease. Arch Intern Med 1991; 151: 245–9PubMedGoogle Scholar
  75. 75.
    Sevush S. Psychopharmacology of Alzheimer’s disease. Hosp Form 1991; 26: 846–52Google Scholar
  76. 76.
    Hopwood MJ, Morris PLP. Drug treatment in Alzheimer’s disease. Aust J Hosp Pharm 1994; 24: 190–3Google Scholar
  77. 77.
    Fleming KC, Evans JM. Pharmacologic therapies in dementia. Mayo Clin Proc 1995; 70: 1116–23PubMedGoogle Scholar
  78. 78.
    Norris FH, Tan Y, Fallat RJ, et al. Trial of oral physostigmine in amyotrophic lateral sclerosis. Clin Pharmacol Ther 1993; 54: 680–2PubMedGoogle Scholar
  79. 79.
    Johnson JT, Ferretti GA, Nethery WJ, et al. Oral pilocarpine for post-irradiation xerostomia with head and neck cancer. N Engl J Med 1993; 329: 390–5PubMedGoogle Scholar
  80. 80.
    Anonymous. Oral pilocarpine for xerostomia. Med Lett Drugs Ther 1994; 36: 76Google Scholar
  81. 81.
    Wiseman LR, Faulds D. Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. Drugs 1995; 49: 143–56PubMedGoogle Scholar
  82. 82.
    Singhal S, Mehta J, Rattenbury H, et al. Oral pilocarpine hydrochloride for the treatment of refractory xerostomia associated with chronic graft-versus-host disease. Blood 1995; 85: 1147–8PubMedGoogle Scholar
  83. 83.
    Salah RS, Cameron OG. Pilocarpine for anticholinergic adverse effects associated with desipramine treatment [letter]. Am J Psychiatry 1996; 153: 579PubMedGoogle Scholar
  84. 84.
    Man-Son-Hing M, Wells G. Meta-analysis of efficacy of quinine for treatment of nocturnal leg cramps in elderly people. BMJ 1995; 310: 13–7PubMedGoogle Scholar
  85. 85.
    Jansen PHP, Veenhuizen KCW, Wesseling AIM, et al. Randomised controlled trial of hydroquinine in muscle cramps. Lancet 1997; 349: 528–32PubMedGoogle Scholar
  86. 86.
    Leclerc KM, Landry FJ. Benign nocturnal leg cramps: current controversies over use of quinine. Postgrad Med 1996; 99: 177–84PubMedGoogle Scholar
  87. 87.
    Quinine for nocturnal leg cramps? Drug Ther Bull 1996; 34: 7–8, 27Google Scholar
  88. 88.
    Clissold SP, Heel RC. Transdermal hyoscine (scopolamine): a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985; 29: 189–207PubMedGoogle Scholar
  89. 89.
    Scopoderm: transdermal hyoscine for motion sickness. Drug Ther Bull 1989; 27: 91–2Google Scholar
  90. 90.
    Honkavaara P, Saarnivaara L, Klemola UM. Prevention of nausea and vomiting with transdermal hyoscine in adults after middle ear surgery during general anaesthesia. Br J Anaesth 1994; 73: 763–6PubMedGoogle Scholar
  91. 91.
    Honkavaara P. Effect of transdermal hyoscine on nausea and vomiting during and after middle ear surgery under local anaesthesia. Br J Anaesth 1996; 76: 49–53PubMedGoogle Scholar
  92. 92.
    Lee TM, Su SF, Chen MF, et al. Usefulness of transdermal scopolamine for vasovagal syncope. Am J Cardiol 1996; 78: 480–2PubMedGoogle Scholar
  93. 93.
    Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med 1993; 329: 1790–6PubMedGoogle Scholar
  94. 94.
    Dronabinol for appetite stimulation in AIDS. Am Pharm 1991; NS31: 467Google Scholar
  95. 95.
    Coodley GO, Loveless MO, Merrill TM. The HIV wasting syndrome: a review. J Acquir Immune Defic Syndr 1994; 7: 681–94PubMedGoogle Scholar
  96. 96.
    Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10: 89–97PubMedGoogle Scholar
  97. 97.
    Mechoulam R, Breuer A, Feigenbaum JJ, et al. Nonpsychotropic synthetic cannabinoids as therapeutic agents. Farmaco 1991; 46 Suppl.: 267–76PubMedGoogle Scholar
  98. 98.
    Snider GL. Theophylline in the ambulatory treatment of chronic obstructive lung disease: resolving a controversy. Cleve Clin J Med 1993; 60: 197–201PubMedGoogle Scholar
  99. 99.
    Ahrens RC. Theophylline — down but not yet out. J Asthma 1995; 32: 85–7PubMedGoogle Scholar
  100. 100.
    Jenne JW. Two new roles for theophylline in the asthmatic? J Asthma 1995; 32: 89–95PubMedGoogle Scholar
  101. 101.
    Yohimbine for male sexual dysfunction. Med Lett Drugs Ther 1994; 36: 115–6Google Scholar
  102. 102.
    De Smet PAGM. Yohimbe alkaloids — general discussion. In: De Smet PAGM, Keller K, Hänsel R, et al., editors. Adverse effects of herbal drugs. Vol. 3. Heidelberg: Springer Verlag, 1997: 181–205Google Scholar
  103. 103.
    Wall ME, Wani MC. Antineoplastic agents from plants. Ann Rev Pharmacol Toxicol 1977; 17: 117–32Google Scholar
  104. 104.
    Cordell GA, Beecher CWW, Pezzuto JM. Can ethnopharmacology contribute to the development of new anticancer drugs? J Ethnopharmacol 1991; 32: 117–33PubMedGoogle Scholar
  105. 105.
    Cragg GM, Boyd MR, Cardelina JH, et al. Role of plants in the National Cancer Institute drugs discovery and development program. In: Kinghorn AD, Balandrin MF, editors. Human medicinal agents from plants: ACS Symposium Series 534. Washington, DC: American Chemical Society, 1993: 80–95Google Scholar
  106. 106.
    Pezzuto JM. Cancer chemoprotective agents: from plant materials to clinical intervention trials. In: Kinghorn AD, Balandrin MF, editors. Human medicinal agents from plants: ACS Symposium Series 534. Washington, DC: American Chemical Society, 1993: 205–15Google Scholar
  107. 107.
    Chabner BA, Allegra CJ, Curt GA, et al. Antineoplastic agents. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1233–87Google Scholar
  108. 108.
    Nelson RL. The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine and vinblastine in human patients with cancer. Med Pediatr Oncol 1982; 10: 115–27PubMedGoogle Scholar
  109. 109.
    Baker JT, Borris RP, Carté B, et al. Natural product drug discovery and development: new perspectives on international collaboration. J Nat Prod 1995; 58: 1325–7PubMedGoogle Scholar
  110. 110.
    Vinorelbine for treatment of advanced non-small-cell lung cancer. Med Lett Drugs Ther 1995; 37: 72–3Google Scholar
  111. 111.
    O’Reilly S, Kennedy MJ, Rowinsky EK, et al. Vinorelbine and the topoisomerase 1 inhibitors: current and potential roles in breast cancer chemotherapy. Breast Cancer Res Treat 1995; 33: 1–17PubMedGoogle Scholar
  112. 112.
    Sorensen JB. Current position of vinorelbine in cancer chemotherapy. Ann Oncol 1995; 6: 105–7PubMedGoogle Scholar
  113. 113.
    Vinorelbine approved for advanced non-small-cell lung cancer. Am J Health Syst Pharm 1995; 52: 678Google Scholar
  114. 114.
    Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360–7PubMedGoogle Scholar
  115. 115.
    Fabi A, Tonachella R, Savarese A, et al. A phase II trial of vinorelbine and thiotepa in metastatic breast cancer. Ann Oncol 1995; 6: 187–9PubMedGoogle Scholar
  116. 116.
    Bruhn JG. The use of natural products in modern medicine. Acta Pharm Nord 1989; 1: 117–30Google Scholar
  117. 117.
    Aapro MS. Oral etoposide and palliative treatment for small-cell lung cancer [commentary]. Lancet 1996; 348: 559PubMedGoogle Scholar
  118. 118.
    Medical Research Council Lung Cancer Working Party. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Lancet 1996; 348: 563–6Google Scholar
  119. 119.
    Slichenmyer WJ, Von Hoff DD. New natural products in cancer chemotherapy. J Clin Pharmacol 1990; 30: 770–88PubMedGoogle Scholar
  120. 120.
    Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332: 1004–14PubMedGoogle Scholar
  121. 121.
    Wani MC, Taylor HL, Wall ME et al. Plant antitumor agents: VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93: 2325–7PubMedGoogle Scholar
  122. 122.
    Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 22: 665–7Google Scholar
  123. 123.
    Gregory RE, DeLisa AF. Paclitaxel: a new antineoplastic agent for refractory ovarian cancer. Clin Pharm 1993; 12: 401–15PubMedGoogle Scholar
  124. 124.
    Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 1994; 344: 1267–72PubMedGoogle Scholar
  125. 125.
    Pouvelle B, Farley PJ, Long CA, et al. Taxol arrests the development of blood-stage Plasmodium falciparum in vitro and Plasmodium chabaudi adami in malaria-infected mice. J Clin Invest 1994; 94: 413–7PubMedGoogle Scholar
  126. 126.
    Brahn E, Tang C, Banquerigo ML. Regression of collagen-induced arthritis with taxol, a microtubule stabilizer. Arthr Rheum 1994; 37: 839–45Google Scholar
  127. 127.
    Song JI, Dumais MR. From yew to us: the curious development of taxol [editorial]. JAMA 1991; 266: 1281PubMedGoogle Scholar
  128. 128.
    Taxol [editorial]. Lancet 1992; 339: 1447–8Google Scholar
  129. 129.
    Nicolaou KC, Guy RK, Potier P. Taxoids: new weapons against cancer. Sci Am 1996: 274(6): 94–8PubMedGoogle Scholar
  130. 130.
    McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273–9PubMedGoogle Scholar
  131. 131.
    Trimble EL, Adams JD, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Treatment Referral Center 9103. J Clin Oncol 1993; 11: 2405–10PubMedGoogle Scholar
  132. 132.
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1–6PubMedGoogle Scholar
  133. 133.
    Neijt JP, Lund B. Paclitaxel with carboplatin for the treatment of ovarian cancer. Semin Oncol 1996; 23Suppl. 15: 2–4PubMedGoogle Scholar
  134. 134.
    Meerpohl HG, Du Bois A, Luck HJ, et al. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial. Semin Oncol 1997; 24Suppl. 2: 17–22Google Scholar
  135. 135.
    Ten Bokkel Huinink W, Veenhof C, Huizing M, et al. Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study. Semin Oncol 1997; 24Suppl. 2: 31–3Google Scholar
  136. 136.
    Paclitaxel now licensed for first-line use in treatment of ovarian cancer. Pharm J 1996; 257: 631Google Scholar
  137. 137.
    Neijt JP. New therapy for ovarian cancer [editorial]. N Engl J Med 1996; 334: 50–1PubMedGoogle Scholar
  138. 138.
    Ozols RF, Vermorken JB. Chemotherapy of advanced ovarian cancer: current status and future directions. Semin Oncol 1997; 24Suppl. 2: 1–9Google Scholar
  139. 139.
    Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797–85PubMedGoogle Scholar
  140. 140.
    Reichman BS, Seidman AD, Crown JP, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11: 1943–51PubMedGoogle Scholar
  141. 141.
    Seidman AD, Reichman BS, Crown JP, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995; 13: 1152–9PubMedGoogle Scholar
  142. 142.
    Tester WJ, Jin PY, Reardon DH, et al. Phase II study of patients with metastatic nonsmall cell carcinoma of the lung treated with paclitaxel by 3-hour infusion. Cancer 1997; 79: 724–9PubMedGoogle Scholar
  143. 143.
    McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer: a gynecologic oncology group study. J Clin Oncol 1996; 14: 792–5PubMedGoogle Scholar
  144. 144.
    Committee for Proprietary Medicinal Products. European Public Assessment Report (EPAR): taxotere. Rev. 2, 1997 Jun 19. http://www.eudra.org/emea.html
  145. 145.
    Martin WR. Docetaxel: a new antineoplastic agent approved by the FDA for the treatment of locally advanced or metastatic breast cancer. Formulary 1996; 31: 891–905Google Scholar
  146. 146.
    Fulton B, Spencer CM. Docetaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 1996; 51: 1075–92PubMedGoogle Scholar
  147. 147.
    Docetaxel (Taxotere) for advanced breast cancer. Med Lett Drugs Ther 1996; 38: 87–8Google Scholar
  148. 148.
    Ardizzoni A. Camptothecin analogues in the treatment of non-small lung cancer. Lung Cancer 1995; 12Suppl. 1: S177–85PubMedGoogle Scholar
  149. 149.
    Rowe PM. Camptothecins: new enthusiasm for an old drug. Lancet 1996; 347: 892PubMedGoogle Scholar
  150. 150.
    Hsiang Y-H, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873–8PubMedGoogle Scholar
  151. 151.
    Wall ME, Wani MC. Camptothecin and taxol: discovery to clinic — thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1995; 55: 753–60PubMedGoogle Scholar
  152. 152.
    Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 709–15PubMedGoogle Scholar
  153. 153.
    Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: 1128–35PubMedGoogle Scholar
  154. 154.
    Wiseman LR, Markham A. Irinotecan: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996; 52: 606–23PubMedGoogle Scholar
  155. 155.
    Irinotecan for metastatic colorectal cancer. Med Lett Drugs Ther 1997; 39: 8Google Scholar
  156. 156.
    Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in thetreatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251–60PubMedGoogle Scholar
  157. 157.
    Fukuoka M, Nitani H, Susuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992; 10: 16–20PubMedGoogle Scholar
  158. 158.
    Shinkai T, Arioka H, Kunikane H, et al. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer. Cancer Res 1994; 54: 2636–42PubMedGoogle Scholar
  159. 159.
    Masuda N, Fukuoka M, Kudoh S, et al. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 1994; 12: 90–6PubMedGoogle Scholar
  160. 160.
    Oshita F, Noda K, Nishiwaki Y, et al. Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. J Clin Oncol 1997; 15: 304–9PubMedGoogle Scholar
  161. 161.
    Dancey J, Eisenhauer EA. Current perspectives on camptothecins in cancer treatment. Br J Cancer 1996; 74: 327–38PubMedGoogle Scholar
  162. 162.
    Shirao K, Shimada Y, Kondo H, et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997; 15: 921–7PubMedGoogle Scholar
  163. 163.
    Barnett AA. FDA approve bark-derived drug. Lancet 1996; 347: 1613PubMedGoogle Scholar
  164. 164.
    Committee for Proprietary Medicinal Products. European Public Assessment Report (EPAR): hycamtin. Rev. 1, 1997 Apr 15. http://www.eudra.org/emea.html
  165. 165.
    Topotecan for metastatic ovarian cancer. Med Lett Drugs Ther 1996; 38: 96–7Google Scholar
  166. 166.
    Ten Bokkel Huinink WW, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183–93PubMedGoogle Scholar
  167. 167.
    Schiller JH, Kim K, Hutson P, et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1996; 14: 2345–52PubMedGoogle Scholar
  168. 168.
    Perez-Soler R, Glisson BS, Lee JS, et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 1996; 14: 2785–90PubMedGoogle Scholar
  169. 169.
    Beran M, Kantarjian H, O’Brien S, et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996; 88: 2473–9PubMedGoogle Scholar
  170. 170.
    Powell RG, Weisleder D, Smith Jr CR. Antitumor alkaloids from Cephalotaxus harringtonia: structure and activity. J Pharm Sci 1972: 61: 1227–30PubMedGoogle Scholar
  171. 171.
    Grem JL, Cheson BD, King SA, et al. Cephalotaxine esters: antileukemic advance or therapeutic failure? J Natl Cancer Inst 1988; 80: 1095–103PubMedGoogle Scholar
  172. 172.
    Ekong RM, Kirby GC, Patel G, et al. Comparison of the in vitro activities of quassinoids with activity against Plasmodium falciparum, anisomycin and some other inhibitors of eukaryotic protein synthesis. Biochem Pharmacol 1990; 40: 297–301PubMedGoogle Scholar
  173. 173.
    O’Dwyer PJ, King SA, Hoth DF, et al. Homoharringtonine — perspectives on an active new natural product. J Clin Oncol 1986; 4: 1563–8PubMedGoogle Scholar
  174. 174.
    Zhou DC, Zittoun R, Marie JP. Homoharringtonine: an effective new natural product in cancer chemotherapy. Bull Cancer 1995; 82: 987–95PubMedGoogle Scholar
  175. 175.
    Warrell Jr RP, Coonley CJ, Gee TS. Homoharringtonine: an effective new drug for remission induction in refractory non-lymphoblastic leukemia. J Clin Oncol 1985; 3: 617–21PubMedGoogle Scholar
  176. 176.
    Kantarjian HM, Keating MJ, Walters RS, et al. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 1989; 63: 813–7PubMedGoogle Scholar
  177. 177.
    Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med 1996; 100: 555–70PubMedGoogle Scholar
  178. 178.
    O’Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995; 86: 3322–6PubMedGoogle Scholar
  179. 179.
    O’Brien S, Kantarjian H, Feldman E, et al. Sequential homoharringtonine (HHT) and interferon (INF-A) produce high hematologic and cytogenetic response rates in Philadelphia chromosome positive (Ph) chronic myelogenous leukemia (CML) [abstract]. Proc Am Soc Clin Oncol 1995; 14: 336Google Scholar
  180. 180.
    Goodwin S, Smith AF, Horning EC. Alkaloids of Ochrosia elliptica Labill. J Am Chem Soc 1959; 81: 1903–8Google Scholar
  181. 181.
    Kan-Fan C, Das BC, Potier P. Alcaloïdes des feuilles d’Ochrosia vieillardii (Apocynacées). Phytochemistry 1970; 9: 1351–2Google Scholar
  182. 182.
    Cosson JP, Schmid M. Les alcaloïdes d’Ochrosia silvatica (Apocynacées). Phytochemistry 1970; 9: 1353–4Google Scholar
  183. 183.
    Svoboda GM, Poore GA, Montfort ML. Alkaloid of Ochrosia maculata Jacq: isolation of the alkaloids and study of the anti-tumor properties of 9-methoxy ellipticine. J Pharm Sci 1968; 57: 1720–5PubMedGoogle Scholar
  184. 184.
    Khayat D, Borel C, Azab M, et al. Phase I study of datelliptium chloride, hydrochloride given by 24-h continuous intravenous infusion. Cancer Chemother Pharmacol 1992; 30: 226–8PubMedGoogle Scholar
  185. 185.
    Acton EM, Narayanan VL, Risbood PA, et al. Anticancer specificity of some ellipticinium salts against human brain tumors in vitro. J Med Chem 1994; 37: 2185–9PubMedGoogle Scholar
  186. 186.
    Jurayj J, Haugwitz RD, Varma RK, et al. Design and synthesis of ellipticinium salts and 1,2-dihydroellipticines with high selectivities against human CNS cancers in vitro. J Med Chem 1994; 37: 2190–7PubMedGoogle Scholar
  187. 187.
    Anderson G, Clavel M, Smyth J, et al. Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung: EORTC Lung Cancer Cooperative Group. Eur J Cancer Clin Oncol 1989; 25: 909–10PubMedGoogle Scholar
  188. 188.
    Nicoletti M, Galeffi C, Messana I, et al. Hypoxidaceae: medicinal uses and the norlignan constituents. J Ethnopharmacol 1992; 36: 95–101PubMedGoogle Scholar
  189. 189.
    Kruger PB, Albrecht CF, Liebenberg RW, et al. Studies on hypoxoside and rooperol analogues from Hypoxis rooperi and Hypoxis latifolia and their biotransformation in man by using high-performance liquid chromatography with in-line sorption enrichment and diode-array detection. J Chromatogr 1994; 662: 71–8Google Scholar
  190. 190.
    Albrecht CF, Kruger PB, Smit BJ, et al. The pharmacokinetic behaviour of hypoxoside taken orally by patients with lung cancer in a phase I trial. S Afr Med J 1995; 85: 861–5PubMedGoogle Scholar
  191. 191.
    Smit BJ, Albrecht CF, Liebenberg RW, et al. A phase I trial of hypoxoside as an oral prodrug for cancer therapy — absence of toxicity. S Afr Med J 1995; 85: 865–70PubMedGoogle Scholar
  192. 192.
    Theron EJ, Albrecht CF, Kruger PB, et al. β-Glucosidase activity in fetal bovine serum renders the plant glucoside, hypoxoside, cytotoxic toward B16-F10-BL-6 mouse melanoma cells. In Vitro Cell Dev Biol Animal 1994; Suppl. 30A: 115–9Google Scholar
  193. 193.
    Igimi H, Tamura R, Toraishi K, et al. Medical solution of gallstones: clinical experiences of d-limonene as a simple, safe, and effective solvent. Dig Dis Sci 1991; 36: 200–8PubMedGoogle Scholar
  194. 194.
    McNamee D. Limonene trial in cancer. Lancet 1993; 342: 801Google Scholar
  195. 195.
    Gould MN. Prevention and therapy of mammary cancer by monoterpenes. J Cell Biochem 1995; 58Suppl. 22: 139–44Google Scholar
  196. 196.
    Poon GK, Vigushin D, Griggs LJ, et al. Identification and characterization of limonene metabolites in patients with advanced cancer by liquid chromatography/mass spectrometry. Drug Metabol Dispos 1996; 24: 565–71Google Scholar
  197. 197.
    Xu B. Recent advances in pharmacologic study of natural anticancer agents in China. Mem Inst Oswaldo Cruz 1991; 86Suppl. 2: 51–4PubMedGoogle Scholar
  198. 198.
    Tang W, Eisenbrand G. Chinese drugs of plant origin: chemistry, pharmacology, and use in traditional and modern medicine. Heidelberg: Springer-Verlag, 1992Google Scholar
  199. 199.
    Lee K-H. Antineoplastic agents and their analogues from Chinese traditional medicine. In: Kinghorn AD, Balandrin MF, editors. Human medicinal agents from plants: ACS Symposium Series 534. Washington, DC: American Chemical Society, 1993: 170–90Google Scholar
  200. 200.
    Han R. Highlight on the studies of anticancer drugs derived from plants in China. Stem Cells 1994; 12: 53–63PubMedGoogle Scholar
  201. 201.
    Zhu Y-P, Woerdenbag HJ. Traditional Chinese herbal medicine. Pharm World Sci 1995; 17: 103–12PubMedGoogle Scholar
  202. 202.
    Ji X, Liu X, Li K, et al. Pharmacological studies of meisoindigo: absorption and mechanism of action. Biomed Environ Sci 1991; 4: 332–7PubMedGoogle Scholar
  203. 203.
    Liu XM, Wang LG, Li HY, et al. Induction of differentiation and down-regulation of c-myb gene expression in ML-1 human myeloblastic leukemia cells by the clinically effective anti-leukemia agent meisoindigo. Biochem Pharmacol 1996; 51: 1545–51PubMedGoogle Scholar
  204. 204.
    Warrell DA, Molyneux ME, Beales PF, et al. Severe and complicated malaria. Trans R Soc Trop Med Hyg 1990; 84Suppl. 2: 1–65Google Scholar
  205. 205.
    Wernsdorfer WH. The development and spread of drug-resistant malaria. Parasitol Today 1991; 7: 297–203PubMedGoogle Scholar
  206. 206.
    White NJ. The treatment of malaria. N Engl J Med 1996; 335: 800–6PubMedGoogle Scholar
  207. 207.
    Pukrittayakamee S, Supanaranond W, Looareesuwan S, et al. Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand. Trans R Soc Trop Med Hyg 1994; 88: 324–7PubMedGoogle Scholar
  208. 208.
    Boele van Hensbroek M, Onyiorah E, Jaffar S, et al. A trial of arthemeter or quinine in children with cerebral malaria. N Engl J Med 1996; 335: 69–75Google Scholar
  209. 209.
    Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985; 228: 1049–55PubMedGoogle Scholar
  210. 210.
    Rediscovering wormwood: qinghaosu for malaria [editorial]. Lancet 1992; 339: 649–51Google Scholar
  211. 211.
    Hien TT, White NJ. Qinghaosu. Lancet 1993; 341: 603–8PubMedGoogle Scholar
  212. 212.
    Barradell LB, Fitton A. Artesunate: a review of its pharmacology and therapeutic efficacy in the treatment of malaria. Drugs 1995; 50: 714–41PubMedGoogle Scholar
  213. 213.
    Woerdenbag HJ, Pras N, Van Uden W, et al. Progress in the research of artemisinin-related antimalarials: an update. Pharm World Sci 1994; 16: 169–80PubMedGoogle Scholar
  214. 214.
    De Vries PJ, Dien TK. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs 1996; 52: 818–36PubMedGoogle Scholar
  215. 215.
    Brewer TG, Grate SJ, Peggins JO, et al. Fatal neurotoxicity of arteether and artemether. Am J Trop Med Hyg 1994; 51: 251–9PubMedGoogle Scholar
  216. 216.
    Wesche DL, DeCoster MA, Tortella FC, et al. Neurotoxicity of artemisinin analogs in vitro. Antimicrob Agents Chemother 1994; 38: 1813–9PubMedGoogle Scholar
  217. 217.
    Hien TTT, Day NPJ, Phu NH, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335: 76–83Google Scholar
  218. 218.
    Miller LG, Panosian CB. Ataxia and slurred speech after artesunate treatment for falciparum malaria [letter]. N Engl J Med 1997; 336: 1328PubMedGoogle Scholar
  219. 219.
    Artemisinin and its derivatives: use as antimalarials. WHO Drug Information 1993; 7: 111–3Google Scholar
  220. 220.
    White NJ. Artemisinin: current status. Trans R Soc Trop Med Hyg 1994; 88Suppl. 1: S3–4PubMedGoogle Scholar
  221. 221.
    Davidson DE. Role of arteether in the treatment of malaria and plans for further development. Trans R Soc Trop Med Hyg 1994; 88Suppl. 1: S51–2PubMedGoogle Scholar
  222. 222.
    Hien TT, Tam DTH, Cuc NTK, et al. Comparative effectiveness of artemisinin suppositories and oral quinine in children with acute falciparum malaria. Trans R Soc Trop Med 1991; 85: 210–1Google Scholar
  223. 223.
    Looareesuwan S. Overview of clinical studies on artemisinin derivatives in Thailand. Trans R Soc Trop Med Hyg 1994; 88Suppl. 1: S9–11PubMedGoogle Scholar
  224. 224.
    Duarte EC, Fontes JF, Gyorkos TW, et al. Randomized controlled trial of artesunate plus tetracycline versus standard treatment (quinine plus tetracycline) for uncomplicated Plasmodium falciparum malaria in Brazil. Am J Trop Med Hyg 1996; 54: 197–202PubMedGoogle Scholar
  225. 225.
    Chinese antimalarial now approved in 27 countries [editorial]. Scrip 1994 Dec 20; 1985: 26Google Scholar
  226. 226.
    Mishra SK, Asthana OP, Mohanty S, et al. Effectiveness of α,β-arteether in acute falciparum malaria. Trans R Soc Trop Med Hyg 1995; 89: 299–301PubMedGoogle Scholar
  227. 227.
    Mohapatra PK, Khan AM, Prakash A, et al. Effect of arteether α/β on uncomplicated falciparum malaria cases in Upper Assam. Indian J Med Res 1996; 104: 284–7PubMedGoogle Scholar
  228. 228.
    Li G-Q, Guo X-B, Fu L-C, et al. Clinical trials of artemisinin and its derivatives in the treatment of malaria in China. Trans R Soc Trop Med Hyg 1994; 88Suppl. 1: S5–6PubMedGoogle Scholar
  229. 229.
    Looareesuwan S, Wilairatana P, Vanijanonta S, et al. Treatment of acute, uncomplicated, falciparum malaria with oral dihydroartemisinin. Ann Trop Med Parasitol 1996; 90: 21–8PubMedGoogle Scholar
  230. 230.
    Ter Kuile F, White NJ, Holloway P, et al. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol 1994; 76: 85–95Google Scholar
  231. 231.
    Udomsangpetch R, Pipitaporn B, Krishna S, et al. Antimalarial drugs reduce cytoadherence and rosetting Plasmodium falciparum. J Infect Dis 1996; 173: 691–8PubMedGoogle Scholar
  232. 232.
    Price RN, Nosten F, Luxemburger C, et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet 1996; 347: 1654–8PubMedGoogle Scholar
  233. 233.
    Nosten F, Luxemburger C, Ter Kuile FO, et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination [published erratum appears in J Infect Dis 1995; 171: 519]. J Infect Dis 1994; 170: 971–7PubMedGoogle Scholar
  234. 234.
    Arnold K. Early treatment of malaria in the community using artemisinin — hope or hazard? Trans R Soc Trop Med Hyg 1994; 88Suppl. 1: S47–9PubMedGoogle Scholar
  235. 235.
    Larkin M. Novel antimalarial agents synthesised. Lancet 1996; 348: 1088Google Scholar
  236. 236.
    Phillipson JD, Wright CW. Can ethnopharmacology contribute to the development of new antimalarial drugs? J Ethnopharmacol 1991; 32: 155–65PubMedGoogle Scholar
  237. 237.
    Phillipson JD, Wright CW. Medicinal plants in tropical medicine: 1. Medicinal plants against protozoal diseases. Trans R Soc Trop Med 1991; 85: 18–21Google Scholar
  238. 238.
    Chang H-M, But PP-H, editors. Pharmacology and applications of Chinese materia medica. Singapore: World Scientific Publishing, 1986–7Google Scholar
  239. 239.
    Vennestrom JL, Klayman DL. Protoberberine alkaloids as antimalarials. J Med Chem 1988; 31: 1084–7Google Scholar
  240. 240.
    Hofheinz W, Buergin H, Gocke E, et al. Ro 42-1611 (arteflene), a new effective antimalarial: chemical structure and biological activity. Trop Med Parasitol 1994; 45: 261–5PubMedGoogle Scholar
  241. 241.
    Jaquet C, Stohler HR, Chollet J, et al. Antimalarial activity of the bicyclic peroxide Ro 42-1611 (arteflene) in experimental models. Trop Med Parasitol 1994; 45: 266–71PubMedGoogle Scholar
  242. 242.
    Asawamahasakda W, Ittarat I, Pu Y-M, et al. Reaction of antimalarial endoperoxides with specific parasite proteins. Antimicrob Agents Chemother 1994; 38: 1854–8PubMedGoogle Scholar
  243. 243.
    Jakobsen PH, Staalso T, Bendtzen K, et al. The antimalarial drug, Ro 42-1611 (arteflene), does not affect cytoadherence and cytokine-inducing properties of Plasmodium falciparum malaria parasites. Trop Med Parasitol 1995; 46: 88–92PubMedGoogle Scholar
  244. 244.
    Salako LA, Guiguemde R, Mittelholzer ML, et al. Ro 42-1611 in the treatment of patients with mild malaria: a clinical trial in Nigeria and Burkina Faso. Trop Med Parasitol 1994; 45: 284–7PubMedGoogle Scholar
  245. 245.
    Somo-Moyou R, Mittelholzer ML, Sorenson F, et al. Efficacy of Ro 42-1611 (arteflene) in the treatment of patients with mild malaria: a clinical trial in Cameroon. Trop Med Parasitol 1994; 45: 288–91PubMedGoogle Scholar
  246. 246.
    Radloff PD, Phillips J, Nkeyi M, et al. Arteflene compared with mefloquine for treating Plasmodium falciparum malaria in children. Am J Trop Med Hyg 1996; 55: 259–62PubMedGoogle Scholar
  247. 247.
    Hänsel R. Phytopharmaka: Grundlagen und Praxis. 2: Auflage. Berlin: Springer-Verlag, 1991Google Scholar
  248. 248.
    Der Marderosian A, Liberti LE. Natural product medicine: a scientific guide to foods, drugs, cosmetics. Philadelphia: George F Stickley Co., 1988Google Scholar
  249. 249.
    Tyler VE. The new honest herbal: a sensible guide to the use of herbs and related remedies. 3rd ed. Binghamton: Pharmaceutical Products Press, 1993Google Scholar
  250. 250.
    Bisset NG, Wichtl M, editors. Herbal drugs and phytopharmaceuticals: a handbook for practice on a scientific basis. Stuttgart: Medpharm Scientific Publishers, 1994Google Scholar
  251. 251.
    Tyler VE. Herbs of choice: the therapeutic use of phytomedicinals. New York: Pharmaceutical Products Press, 1994Google Scholar
  252. 252.
    Newall CA, Anderson LA, Phillipson JD. Herbal medicines: a guide for health-care professionals. London: Pharmaceutical Press, 1996Google Scholar
  253. 253.
    Leung AY, Foster S. Encyclopedia of common natural ingredients used in food, drugs, and cosmetics. 2nd ed. New York: John Wiley and Sons, Inc., 1996Google Scholar
  254. 254.
    Hänsel R, Keller K, Rimpler H, et al. Hagers Handbuch der pharmazeutischen Praxis. 5th ed. Band 4-Band 6. Berlin: Springer-Verlag, 1992–4Google Scholar
  255. 255.
    Wichtl M, editor. Teedrogen und Phytopharmaka: ein Handbuch für die Praxis auf wissenschaftlicher Grundlage. 3: Auflage. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1997Google Scholar
  256. 256.
    Germany leads in branded phytomedicines. OTC Bull 1996 Jun 14; 15Google Scholar
  257. 257.
    Smith MBH, Feldman W. Over-the-counter cold medications: a critical review of clinical trials between 1950 and 1991. JAMA 1993; 269: 2258–63PubMedGoogle Scholar
  258. 258.
    Wenzel P, Wegener T. Teufelskralle — ein pflanzliches Antirheumatikum. Dtsch Apoth Ztg 1995; 135: 1131–44Google Scholar
  259. 259.
    Holz W, Schwarze H. Harpagophytum. In: Hänsel R, Keller K, Rimpler H, et al., editors. Hagers Handbuch der pharmazeutischen Praxis. 5th ed. Band 5: Drogen E-O. Berlin: Springer-Verlag, 1993: 384–90Google Scholar
  260. 260.
    Chrubasik S, Zimpfer Ch, Schütt U, et al. Effectiveness of Harpagophytum procumbens in treatment of acute low back pain. Phytomedicine 1996; 3: 1–10Google Scholar
  261. 261.
    Ewe K, Lemli J, Leng-Peschlow E, et al. Proceedings Second International Symposium on Senna. Pharmacology 47Suppl. 1: 1–262Google Scholar
  262. 262.
    Klein AD, Penneys NS. Aloe vera [published erratum in J Am Acad Dermatol 1988; 19: 82]. J Am Acad Dermatol 1988; 18: 714–20PubMedGoogle Scholar
  263. 263.
    Marshall JM. Aloe vera gel: what is the evidence? Pharm J 1990; 244: 360–2Google Scholar
  264. 264.
    Shelton RM. Aloe vera: its chemical and therapeutic properties. Int J Dermatol 1991; 30: 679–83PubMedGoogle Scholar
  265. 265.
    Schmidt JM, Greenspoon JS. Aloe vera dermal wound gel is associated with a delay in wound healing. Obstet Gynecol 1991; 78: 115–7PubMedGoogle Scholar
  266. 266.
    Williams MS, Burk M, Loprinzi CL, et al. Phase III doubleblind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicity. Int J Radiation Oncol Biol Phys 1996; 36: 345–9Google Scholar
  267. 267.
    Syed TA, Ahmad SA, Holt AH, et al. Management of psoriasis with Aloe vera extract in a hydrophilic cream: a placebo-controlled, double-blind study. Trop Med Int Health 1996; 1: 505–9PubMedGoogle Scholar
  268. 268.
    Yongchaiyudha S, Rungpitarangsi V, Bunyapraphatsara N, et al. Antidiabetic activity of Aloe vera L. juice: I. Clinical trial in new cases of diabetes mellitus. Phytomedicine 1996; 3: 241–3Google Scholar
  269. 269.
    Bunyapraphatsara N, Yongchaiyudha S, Rungpitarangsi V, et al. Antidiabetic activity of Aloe vera L. juice: II. Clinical trial in diabetes mellitus patients in combination with glibenclamide. Phytomedicine 1996; 3: 245–8Google Scholar
  270. 270.
    Avorn J, Monane M, Gurwitz JH, et al. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA 1994; 271: 751–4PubMedGoogle Scholar
  271. 271.
    Avorn J, Monane M, Gurwitz JH, et al. Reduction of bacteriuria and pyuria using cranberry juice [letter]. JAMA 1994; 272: 589Google Scholar
  272. 272.
    Gamolenic acid in atopic eczema: Epogam. Drug Ther Bull 1990; 28: 69–70Google Scholar
  273. 273.
    Gamolenic acid (Efamast) — for benign breast pain. Drug Ther Bull 1991; 29: 18–9Google Scholar
  274. 274.
    Kleijnen J. Evening primrose oil. Currently used in many conditions with little justification [editorial]. BMJ 1994; 309: 824–5PubMedGoogle Scholar
  275. 275.
    Biagi PL, Bordoni A, Hrelia S, et al. The effect of gammalinolenic acid on clinical status, red cell fatty acid composition and membrane microviscosity in infants with atopic dermatitis. Drugs Exp Clin Res 1994; 20: 77–84PubMedGoogle Scholar
  276. 276.
    Humphreys F, Symons JA, Brown HK, et al. The effects of gamolenic acid on adult atopic eczema and premenstrual exacerbation of eczema. Eur J Dermatol 1994; 4: 598–603Google Scholar
  277. 277.
    Hederos CA, Berg A. Epogam evening primrose oil treatment in atopic dermatitis and asthma. Arch Dis Child 1996; 75: 494–7PubMedGoogle Scholar
  278. 278.
    Chenoy R, Hussain S, Tayob Y, et al. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. BMJ 1994; 308: 501–3PubMedGoogle Scholar
  279. 279.
    Whitaker DK, Cilliers J, De Beer C. Evening primrose oil (Epogam) in the treatment of chronic hand dermatitis: disappointing therapeutic results. Dermatology 1996; 193: 115–20PubMedGoogle Scholar
  280. 280.
    Oliwiecki S, Burton JL. Evening primrose oil and marine oil in the treatment of psoriasis. Clin Exp Dermatol 1994; 19: 127–9PubMedGoogle Scholar
  281. 281.
    Veale DJ, Torley HI, Richards IM, et al. A double-blind placebo controlled trial of Efamol Marine on skin and joint symptoms of psoriatic arthritis. Br J Rheumatol 1994; 33: 954–8PubMedGoogle Scholar
  282. 282.
    Johnson ES, Kadam NP, Hylands DM, et al. Efficacy of fever-few as prophylactic treatment of migraine. BMJ 1985; 291: 569–73PubMedGoogle Scholar
  283. 283.
    Murphy JJ, Heptinstall S, Mitchell JRA. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988; 2: 189–92PubMedGoogle Scholar
  284. 284.
    Awang DVC. Feverfew. Can Pharm J 1989; 122: 266–70Google Scholar
  285. 285.
    Awang DVC. Feverfew fever: a headache for the consumer. Herbalgram 1993; 29: 34–36, 66Google Scholar
  286. 286.
    De Weerdt CJ, Bootsma HPR, Hendriks H. Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine 1996; 3: 225–30Google Scholar
  287. 287.
    Simon HB. Patient-directed, nonprescription approaches to cardiovascular disease. Arch Intern Med 1994; 154: 2283–96PubMedGoogle Scholar
  288. 288.
    Beaglehole R. Garlic for flavour, not cardioprotection [commentary]. Lancet 1996; 348: 1186–7PubMedGoogle Scholar
  289. 289.
    Orekhov AN, Tertov VV, Sobenin IA, et al. Direct anti-atherosclerosis-related effects of garlic. Ann Med 1995; 27: 63–5PubMedGoogle Scholar
  290. 290.
    Morris J, Burke V, Mori TA, et al. Effects of garlic extract on platelet aggregation: a randomized placebo-controlled double-blind study. Clin Exp Pharmacol Physiol 1995; 22: 414–7PubMedGoogle Scholar
  291. 291.
    Silagy CA, Neil HAW. A meta-analysis of the effect of garlic on blood pressure. J Hypertens 1994; 12: 463–8PubMedGoogle Scholar
  292. 292.
    Kleijnen J, Knipschild P, Ter Riet G. Garlic, onions and cardiovascular risk factors: a review of the evidence from human experiments with emphasis on commercially available preparations. Br J Clin Pharmacol 1989; 28: 535–44PubMedGoogle Scholar
  293. 293.
    Warshafsky S, Kamer RS, Sivak SL. Effect of garlic on total serum cholesterol: a meta-analysis. Ann Intern Med 1993; 119: 599–605PubMedGoogle Scholar
  294. 294.
    Kamer RS, Warshafsky S, Sivak SL. Does eating garlic lower cholesterol? Ann Intern Med 1994; 120: 969–70Google Scholar
  295. 295.
    Silagy C, Neil A. Garlic as a lipid lowering agent — a meta-analysis. J R Coll Phys Lond 1994; 28: 39–45Google Scholar
  296. 296.
    Simons LA, Balasubramaniam S, Von Konigsmark M, et al. On the effect of garlic on plasma lipids and lipoproteins in mild hypercholesterolaemia. Atherosclerosis 1995; 113: 219–25PubMedGoogle Scholar
  297. 297.
    Neil HAW, Silagy CA, Lancaster T, et al. Garlic powder in the treatment of moderate hyperlipidaemia: a controlled trial and meta-analysis. J R Coll Phys London 1996; 30: 329–34Google Scholar
  298. 298.
    Sticher O. Beurteilung von Knoblauchpräparaten. Dtsch Apoth Ztg 1991; 131: 403–13Google Scholar
  299. 299.
    Lawson LD, Wang Z-YJ, Highes BG. Identification and HPLC quantitation of the sulfide and dialk(en)yl thiosulfinates in commercial garlic products. Planta Med 1991; 57: 363–70PubMedGoogle Scholar
  300. 300.
    Pentz R, Guo Z, Müller B, et al. Standardisierung von Knoblauchpräparaten: Untersuchung von 22 Fertigarzneimitteln. Dtsch Apoth Ztg 1992; 132: 1779–82Google Scholar
  301. 301.
    Mowrey DB, Clayson DE. Motion sickness, ginger and psycho-physics. Lancet 1982; I: 655–7Google Scholar
  302. 302.
    Grøntved A, Hentzer E. Vertigo-reducing effect of ginger root: a controlled clinical study. ORL J Otorhinolaryngol Relat Spec 1986; 48: 282–6PubMedGoogle Scholar
  303. 303.
    Grøntved A, Brask T, Kambskard J, et al. Ginger root against seasickness: a controlled trial on the open sea. Acta Otolaryngol 1988; 105: 45–9PubMedGoogle Scholar
  304. 304.
    Holtmann S, Clarke AH, Scherer H, et al. The anti-motion sickness mechanism of ginger: a comparative study with placebo and dimenhydrinate. Acta Otolaryngol 1989; 108: 168–74PubMedGoogle Scholar
  305. 305.
    Kawai T, Kinoshita K, Koyama K, et al. Anti-emetic principles of Magnolia obovata bark and Zingiber officinale rhizome. Planta Med 1994; 60: 17–20PubMedGoogle Scholar
  306. 306.
    Bone ME, Wilkinson DJ, Young JR, et al. Ginger root — a new antiemetic: the effect of ginger root on postoperative nausea and vomiting after major gynaecological surgery. Anaesthesia 1990; 45: 669–71PubMedGoogle Scholar
  307. 307.
    Arfeen Z, Owen H, Plummer JL, et al. A double-blind randomized controlled trial of ginger for the prevention of postoperative nausea and vomiting. Anaesth Intens Care 1995; 23: 449–52Google Scholar
  308. 308.
    Fischer-Rasmussen W, Kjaer SK, Dahl C, et al. Ginger treatment of hyperemesis gravidarum. Eur J Obst Gynecol Rep Biol 1991; 38: 19–24Google Scholar
  309. 309.
    Kruik-Smits JCM. Gemberextract tegen gewrichtspijn. Pharm Weekbl 1996; 131: 1261Google Scholar
  310. 310.
    Corrigan D. Zingiber officinale. In: De Smet PAGM, Keller K, Hänsel R, et al., editors. Adverse effects of herbal drugs. Vol. 3. Heidelberg: Springer-Verlag, 1997: 215–28Google Scholar
  311. 311.
    Holdsclaw VA, Nykamp D. Treating poisonings: focus on syrup of ipecac. Syrup of ipecac is the most useful emetic agent in the home treatment of poisoning. Am Pharm 1992; 32(7): 31–3Google Scholar
  312. 312.
    Bond GR, Requa RK, Krenzelok EP, et al. Influence of time until emesis on the efficacy of decontamination using acetaminophen as a marker in a pediatric population. Ann Emerg Med 1993; 22: 1403–7PubMedGoogle Scholar
  313. 313.
    Phillips S, Gomez H, Brent J. Pediatric gastrointestinal decontamination in acute toxin ingestion. J Clin Pharmacol 1993; 33: 497–507PubMedGoogle Scholar
  314. 314.
    Bond GR. Home use of syrup of ipecac is associated with a reduction in pediatric emergency department visits. Ann Emerg Med 1995; 25: 338–43PubMedGoogle Scholar
  315. 315.
    American College of Emergency Physicians. Clinical policy for the initial approach to patients presenting with acute toxic ingestion or dermal or inhalation exposure. Ann Emerg Med 1995; 25: 570–85Google Scholar
  316. 316.
    Vale JA, Proudfoot AT. Paracetamol (acetaminophen) poisoning. Lancet 1995; 346: 547–52PubMedGoogle Scholar
  317. 317.
    Harris CR, Kingston R. Gastrointestinal decontamination: which method is best? Postgrad Med 1992; 92: 116–28PubMedGoogle Scholar
  318. 318.
    Pond SM, Lewis-Driver DJ, Williams GM, et al. Gastric emptying in acute overdose: a prospective randomised controlled trial. Med J Aust 1995; 163: 345–9PubMedGoogle Scholar
  319. 319.
    Minton N, Swift R, Lawlor C, et al. Ipecacuanha-induced emesis: a human model for testing antiemetic drug activity. Clin Pharmacol Ther 1993; 54: 53–7PubMedGoogle Scholar
  320. 320.
    Bell LP, Hectorne K, Reynolds H, et al. Cholesterol-lowering effects of psyllium hydrophilic mucilloid: adjunct therapy to a prudent diet for patients with mild to moderate hypercholesterolemia. JAMA 1989; 261: 3419–23PubMedGoogle Scholar
  321. 321.
    Levin EG, Miller VT, Muesing RA, et al. Comparison of psyllium hydrophilic mucilloid and cellulose as adjuncts to a prudent diet in the treatment of mild to moderate hypercholesterolemia. Arch Intern Med 1990; 150: 1822–7PubMedGoogle Scholar
  322. 322.
    Anderson JW, Floore TL, Geil PB, et al. Hypocholesterolemic effects of different bulk-forming hydrophilic fibers as adjuncts to dietary therapy in mild to moderate hypercholesterolemia. Arch Intern Med 1991; 151: 1597–602PubMedGoogle Scholar
  323. 323.
    Sprecher DL, Harris BV, Goldberg AC, et al. Efficacy of psyllium in reducing serum cholesterol levels in hypercholesterolemic patients on high- or low-fat diets. Ann Intern Med 1993; 119: 545–54PubMedGoogle Scholar
  324. 324.
    Pearson TA, Patel RV. The quest for a cholesterol-decreasing diet: should we subtract, substitute, or supplement? Ann Intern Med 1993; 119: 627–8PubMedGoogle Scholar
  325. 325.
    Spence JD, Huff MW, Heidenheim P, et al. Combination therapy with colestipol and psyllium mucilloid in patients with hyper-lipidemia. Ann Intern Med 1995; 123: 493–9PubMedGoogle Scholar
  326. 326.
    Bassett IB, Pannowitz DL, Barnetson RS. A comparative study of tea-tree oil versus benzoylperoxide in the treatment of acne. Med J Aust 1990; 153: 455–8PubMedGoogle Scholar
  327. 327.
    Buck DS, Nidorf DM, Addino JG. Comparison of two topical preparations for the treatment of onychomycosis: Melaleuca alternifolia (tea tree) oil and clotrimazole. J Fam Pract 1994; 38: 601–5PubMedGoogle Scholar
  328. 328.
    Carson CF, Riley TV. Antimicrobial activity of the major components of the essential oil of Melaleuca alternifolia. J Appl Bacteriol 1995; 78: 264–9PubMedGoogle Scholar
  329. 329.
    Thompson WG. Doubts about bran [commentary]. Lancet 1994; 344: 3PubMedGoogle Scholar
  330. 330.
    Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet 1994; 344: 39–40PubMedGoogle Scholar
  331. 331.
    Oh VMS. The placebo effect: can we use it better? Placebos work best for pain, disorders of autonomic sensation, and disorders of factors under neurohumoral control. BMJ 1994; 309: 69–70PubMedGoogle Scholar
  332. 332.
    Porsius AJ. Kwaliteitsaspecten van farmacotherapie. Genees-middelenbulletin 1994; 28: 18–21Google Scholar
  333. 333.
    Bos R, Woerdenbag HJ, Hendriks H, et al. Analytical aspects of phytotherapeutic valerian preparations. Phytochem Anal 1996; 7: 143–51Google Scholar
  334. 334.
    Ray WA, Griffin MR, Avorn J. Evaluating drugs after their approval for clinical use. N Engl J Med 1993; 329: 2029–32PubMedGoogle Scholar
  335. 335.
    De Smet PAGM, Stricker BHCh, Nijman JJ. Indirecte risico’s van alternatieve middelen — een oproep tot het rapporteren van concrete gevallen. Med Contact 1994; 49: 1593–4Google Scholar
  336. 336.
    Downer SM, Cody MM, McCluskey P, et al. Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ 1994; 309: 86–9PubMedGoogle Scholar
  337. 337.
    Galloway JH, Farmer K, Weeks GR, et al. Potentially hazardous compound in a herbal slimming remedy Drug Ther Bull[letter]. Lancet 1992; 340: 179PubMedGoogle Scholar
  338. 338.
    De Smet PAGM, Smeets OSNM. Potential risks of health food products containing yohimbe extracts [letter]. BMJ 1994; 309: 958PubMedGoogle Scholar
  339. 339.
    De Smet PAGM. Toxicological outlook on the quality assurance of herbal remedies. In: De Smet PAGM, Keller K, Hänsel R, et al., editors. Adverse effects of herbal drugs. Vol. 1. Heidelberg: Springer-Verlag, 1992: 1–72Google Scholar
  340. 340.
    De Smet PAGM. Should herbal medicine-like products be licensed as medicines: special licensing seems the best way forward [editorial]. BMJ 310: 1023–4Google Scholar
  341. 341.
    De Smet PAGM, Brouwers JRBJ. Pharmacokinetic evaluation of herbal remedies: basic introduction, applicability, current status and regulatory needs. Clin Pharmacokinet 1997; 32: 427–36PubMedGoogle Scholar
  342. 342.
    Grünwald J, Büttel K. The European phytotherapeutics market: figures, trends, analyses. Drugs Made in Germany 1996; 39: 6–11Google Scholar
  343. 343.
    Schwabe U, Paffrath D, editors. Arzneiverordnungs-Report’ 96: aktuelle Daten, Kosten, Trends und Kommentare. Stuttgart: Gustav Fischer Verlag, 1996Google Scholar
  344. 344.
    Schwabe U. Durchblutungsfördernde Mittel. In: Schwabe U, Paffrath D, editors. Arzneiverordnungs-Report’ 96: aktuelle Daten, Kosten, Trends und Kommentare. Stuttgart: Gustav Fischer Verlag, 1996: 227–37Google Scholar
  345. 345.
    Kleijnen J. Food supplements and their efficacy [Ph.D. thesis]. Maastricht: Univ of Limburg, 1991Google Scholar
  346. 346.
    Kleijnen J, Knipschild P Ginkgo biloba. Lancet 1992; 340: 1136–9PubMedGoogle Scholar
  347. 347.
    Ernst E. Ginkgo biloba in der Behandlung der Claudicatio intermittens: eine systematische Recherche anhand kontrollierter Studien in der Literatur. Fortschr Med 1996; 114: 85–7PubMedGoogle Scholar
  348. 348.
    Drabaek H, Petersen JP, Wiinberg N, et al. Effekten af Ginkgo biloba-ekstrakt hos patienter med claudicatio intermittens. Ugeskr Laeger 1996; 158: 3928–31PubMedGoogle Scholar
  349. 349.
    RVG 18753 — Tavonin tabletten. Rijswijk, College ter Beoordeling van Geneesmiddelen, 1996 Dec 9Google Scholar
  350. 350.
    Braquet P, Hosford D. Ethnopharmacology and the development of natural PAF antagonists as therapeutic agents. J Ethnopharmacol 1991; 32: 135–9PubMedGoogle Scholar
  351. 351.
    Guinot P. Clinical experience with platelet-activating factor antagonists: past, present, and near future. Clin Rev Allergy 1994; 12: 397–417PubMedGoogle Scholar
  352. 352.
    Dhainaut J-FA, Tenaillon A, LeTulzo Y, et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1994; 22: 1720–8PubMedGoogle Scholar
  353. 353.
    Grino JM. BN 52021: a platelet activating factor antagonist for preventing post-transplant renal failure: a double-blind, randomized study. Ann Intern Med 1994; 121: 345–7PubMedGoogle Scholar
  354. 354.
    Brochet B, Guinot P, Orgogozo JM, et al. Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. J Neurol Neurosurg Psychiat 1995; 58: 360–2PubMedGoogle Scholar
  355. 355.
    Nathan N, Mercury P, Denizot Y, et al. Effects of the platelet-activating factor receptor antagonist BN 52021 on hematologic variables and blood loss during and after cardiopulmonary bypass. Anesth Analg 1994; 79: 205–11PubMedGoogle Scholar
  356. 356.
    Schmitz W. Urologika. In: Schwabe U, Paffrath D, editors. Arzneiverordnungs-Report’ 96: aktuelle Daten, Kosten, Trends und Kommentare. Stuttgart: Gustav Fischer Verlag, 1996: 438–48Google Scholar
  357. 357.
    Plosker GL, Brogden RN. Serenoa repens (Permixon®). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996; 9: 379–95PubMedGoogle Scholar
  358. 358.
    Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996; 29: 231–40PubMedGoogle Scholar
  359. 359.
    Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335: 533–9PubMedGoogle Scholar
  360. 360.
    Adriazola Semino M, Lozano Ortega JL, García Cobo E, et al. Symptomatic treatment of benign hypertrophy of the prostate: comparative study of prazosin and Serenoa repens. Arch Esp Urol 1992; 45: 211–3PubMedGoogle Scholar
  361. 361.
    Grasso M, Montesano A, Buonaguidi A, et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol 1995; 48: 97–103PubMedGoogle Scholar
  362. 362.
    Ammon HPT, Kaul R. Crataegus: Herz-Kreislauf-Wirkungen von Crataegusextrakten, Flavonoiden und Procyanidinen. Teil 1: Historisches und Wirkstoffe. Dtsch Apoth Ztg 1994; 134: 2433–6Google Scholar
  363. 363.
    Ammon HPT, Kaul R. Crataegus: Herz-Kreislauf-Wirkungen von Crataegusextrakten, Flavonoiden und Procyanidinen. Teil 2: Wirkungen auf das Herz. Dtsch Apoth Ztg 1994; 134: 2521–35Google Scholar
  364. 364.
    Ammon HPT, Kaul R. Crataegus. Herz-Kreislauf-Wirkungen von Crataegusextrakten, Flavonoiden und Procyanidinen. Teil 3: Wirkungen auf den Kreislauf. Dtsch Apoth Ztg 1994; 134: 2631–6Google Scholar
  365. 365.
    Weihmayr Th, Ernst E. Die therapeutische Wirksamkeit von Crataegus. Fortschr Med 1996; 114: 27–9PubMedGoogle Scholar
  366. 366.
    Leuchtgens H. Crataegus-Spezialextrakt WS 1442 bei Herzinsuffizienz NYHA II: eine placebokontrollierte randomisierte Doppelblindstudie. Fortschr Med 1993; 111: 352–4PubMedGoogle Scholar
  367. 367.
    Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450–6PubMedGoogle Scholar
  368. 368.
    Scholz H. Kardiaka. In: Schwabe U, Paffrath D, editors. Arzneiverordnungs-Report’ 96: aktuelle Daten, Kosten, Trends und Kommentare. Stuttgart: Gustav Fischer Verlag, 1996: 276–81Google Scholar
  369. 369.
    Diehm C, Trampisch HJ, Lange S, et al. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet 1996; 347: 292–4PubMedGoogle Scholar
  370. 370.
    Venostasin contra Kompressionsstrümpfe [editorial]. Arznei-Telegramm 1996; 5: 47–8Google Scholar
  371. 371.
    Kinzler E, Krömer J, Lehmann E. Wirksamkeit eines Kava-Spezial-Extraktes bei Patienten mit Angst-, Spannungs- und Erregungszuständen nicht-psychotischer Genese. Doppel-blind-Studie gegen Plazebo über 4 Wochen. Arzneimittel Forschung 1991; 41: 584–8PubMedGoogle Scholar
  372. 372.
    Woelk H, Kapoula O, Lehrl S, et al. Behandlung von Angst-Patienten: Doppelblindstudie. Kava-Spezialextrakt WS 1490 versus Benzodiazepine. Z Allgemeinmed 1993; 69: 271–7Google Scholar
  373. 373.
    Hölzl J. Die polynesische Arzneipflanze Kava: gut wirksam bei Angstzuständen. Therapiewoche 1994; 44: 796–802Google Scholar
  374. 374.
    Nutzen und Risiken von Kava-Kava-Präparaten (Kavosporal, Laitan u.a.). Arznei-Telegramm 1995; 6: 66Google Scholar
  375. 375.
    Berges RR, Windeler J, Trampisch HJ, et al. Randomised, placebo-controlled, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia. Lancet 1995; 345: 1529–32PubMedGoogle Scholar
  376. 376.
    Oesterling JE. Benign prostatic hyperplasia: medical and minimally invasive treatment options. N Engl J Med 1995; 332: 99–109PubMedGoogle Scholar
  377. 377.
    Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991; 337: 1457–61PubMedGoogle Scholar
  378. 378.
    Linde K, Ramirez G, Mulrow CD, et al. St John’s wort for depression — an overview and meta-analysis of randomised clinical trials. BMJ 1996; 313: 253–8PubMedGoogle Scholar
  379. 379.
    Guidelines on psychotropic drugs for the EC. Eur Neuropsychopharmacol 1994; 4: 61–77Google Scholar
  380. 380.
    De Smet PAGM, Nolen WA. St John’s wort as an antidepressant: longer term studies are needed before it can be recommended in major depression [editorial]. BMJ 1996; 313: 241–2PubMedGoogle Scholar
  381. 381.
    Zinn C. Canberra legalises cannabis for patients in trials. BMJ 1994; 309: 1532PubMedGoogle Scholar
  382. 382.
    Macready N. Two more US states approve of cannabis. BMJ 1996; 313: 1224PubMedGoogle Scholar
  383. 383.
    Tarleton Landis N. California, Arizona laws permit medical use of marijuana. Am J Health-Syst Pharm 1997; 54: 126, 128, 132Google Scholar
  384. 384.
    Kassirer JP. Federal foolishness and marijuana [editorial]. N Engl J Med 1997; 336: 366–7PubMedGoogle Scholar
  385. 385.
    Grinspoon L, Bakalar JB. Marihuana as a medicine: a plea for reconsideration [editorial]. JAMA 1995; 273: 1875–6PubMedGoogle Scholar
  386. 386.
    Doyle E, Spence AA. Cannabis as a medicine? [editorial] Br J Anaesth 1995; 74: 359–61PubMedGoogle Scholar
  387. 387.
    Gezondheidsraad: Beraadsgroep Geneeskunde: Marihuana als medicijn. Publicatie nr 1996/21. Rijswijk: Gezondheidsraad, 1996Google Scholar
  388. 388.
    Voelker R. NIH panel says more study is needed to assess marijuana’s medicinal use. JAMA 1997; 277: 867–8PubMedGoogle Scholar
  389. 389.
    Kassirer JP Medicinal marijuana? N Engl J Med 1997; 336: 1186–7Google Scholar
  390. 390.
    Pharmaceuticals from plants: great potential, few funds [editorial]. Lancet 1994; 343: 1513–5Google Scholar
  391. 391.
    Phillipson JD. Natural products as drugs. Trans R Soc Trop Med Hyg 1994; 88Suppl. 1: 17–9Google Scholar
  392. 392.
    Phillipson JD. Traditional medicine treatment for eczema: experience as a basis for scientific acceptance. Eur Phytotelegram 1994; 6: 33–40Google Scholar
  393. 393.
    Bos JD, Kapsenberg ML, Sillevis Smit JH. Pathogenesis of atopic eczema. Lancet 1994; 343: 1338–41PubMedGoogle Scholar
  394. 394.
    Sheehan MP, Rustin MH, Atherton DJ, et al. Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. Lancet 1992; 340: 13–7PubMedGoogle Scholar
  395. 395.
    Sheehan MP, Atherton DJ. A controlled trial of traditional Chinese medicinal plants in widespread non-exudative atopic eczema. Br J Dermatol 1992; 126: 179–84PubMedGoogle Scholar
  396. 396.
    Sheehan MP, Atherton DJ. One year follow-up of children treated with Chinese medicinal herbs for atopic eczema. Br J Dermatol 1994; 130: 484–93Google Scholar
  397. 397.
    Sheehan MP, Stevens H, Ostlere LS, et al. Follow-up of adult patients with atopic eczema treated with Chinese herbal therapy for 1 year. Clin Exp Dermatol 1995; 20: 136–40PubMedGoogle Scholar
  398. 398.
    Perharic L, Shaw D, Leon C, et al. Possible association of liver damage with the use of Chinese herbal medicine for skin disease. Vet Hum Toxicol 1995; 37: 562–6PubMedGoogle Scholar
  399. 399.
    Ruston M, Atherton D. Toxicity of Chinese herbal remedies. Lancet 1992; 340: 673–4Google Scholar
  400. 400.
    Latchman Y, Bungy GA, Atherton DJ, et al. Efficacy of traditional Chinese herbal therapy in vitro: a model system for atopic eczema. Inhibition of CD23 expression on blood monocytes. Br J Dermatol 1995; 132: 592–8PubMedGoogle Scholar
  401. 401.
    Latchman Y, Banerjee P, Poulter LW, et al. Association of immunological changes with clinical efficacy in atopic eczema patients treated with traditional Chinese herbal therapy (Zemaphyte®). Int Arch Allergy Immunol 1996; 109: 243–9PubMedGoogle Scholar
  402. 402.
    Xu X-J, Banerjee P, Rustin MHA, et al. Modulation by Chinese herbal therapy of immune mechanisms in the skin of patients with atopic eczema. Br J Dermatol 1997; 136: 54–9PubMedGoogle Scholar
  403. 403.
    Phytopharm’s eczema herbs. Pharm J 1996; 257: 630Google Scholar
  404. 404.
    Bensoussan A, Myers SP. Towards a safer choice: the practice of traditional Chinese medicine in Australia. Campbelltown: Univ Western Sydney Macarthur, 1996: 341–66Google Scholar
  405. 405.
    Kessels AG, Cardynaals RL, Borger RL, et al. The effectiveness of the hair-restorer ‘Dabao’ in males with alopecia androgenetica: a clinical experiment. J Clin Epidemiol 1991; 44: 439–47PubMedGoogle Scholar
  406. 406.
    Kong X-T, Fang HT, Jiang GQ, et al. Treatment of acute bronchiolitis with Chinese herbs. Arch Dis Child 1993; 68: 468–71PubMedGoogle Scholar
  407. 407.
    Everard NL. Bronchiolitis: origins and optimal management. Drugs 1995; 49: 885–96PubMedGoogle Scholar
  408. 408.
    Dawson K. Rational prescribing for acute bronchiolitis. PharmacoEconomics 1995; 8: 9–13PubMedGoogle Scholar
  409. 409.
    Chen H-C, Hsieh M-T. Clinical trial of suanzaorentang in the treatment of insomnia. Clin Ther 1985; 7: 334–7PubMedGoogle Scholar
  410. 410.
    Chen HC, Hsieh MT, Shibuya TK. Suanzaorentang versus diazepam: a controlled double-blind study in anxiety. Int J Clin Pharmacol Ther Toxicol 1986; 24: 646–50PubMedGoogle Scholar
  411. 411.
    Hsieh MT, Chen HC. Suanzaorentang in cardiac patients with anxiety. Eur J Clin Pharmacol 1986; 30: 481–4PubMedGoogle Scholar
  412. 412.
    Hsieh MT, Chen HC, Hsu PH, et al. Effects of suanzaorentang on behavior changes and central monoamines. Proc Nat Sci Council Rep China Part B Life Sci 1986; 10: 43–8Google Scholar
  413. 413.
    Hsieh MT, Chen HC, Kao HC, et al. Suanzaorentang, and anxiolytic Chinese medicine, affects the central adrenergic and serotonergic systems in rats. Proc Nat Sci Council Rep China Part B Life Sci 1986; 10: 263–8Google Scholar
  414. 414.
    Chen HC, Hsieh MT. Hemodynamic effects of orally administered sunitang in humans. Clin Pharmacol Ther 1987; 41: 496–501PubMedGoogle Scholar
  415. 415.
    Chen HC, Hsieh MT, Chang SS, et al. Long-term reno-cardiovascular effects of orally administered aconiti tuber in humans. Am J Chin Med 1990; 18: 25–33PubMedGoogle Scholar
  416. 416.
    De Smet PAGM. Tripterygium species. In: De Smet PAGM, Keller K, Hänsel R, et al., editors. Adverse effects of herbal drugs. Vol. 3. Heidelberg: Springer-Verlag, 1997: 145–63Google Scholar
  417. 417.
    Xu F, Huang JB, Jiang L, et al. Amelioration of cyclosporin nephrotoxicity by Cordyceps sinensis in kidney-transplanted recipients. Nephrol Dial Transplant 1995; 10: 142–3PubMedGoogle Scholar
  418. 418.
    Zhilian M, Jun Q, Youhua Z, et al. Application of Corbrin capsule in human renal transplantation. Transplant Proc 1996; 28: 1626–8Google Scholar
  419. 419.
    Hanin I, Tang XC, Kindel GL, et al. Natural and synthetic huperzine A: effect on cholinergic function in vitro and in vivo. Ann NY Acad Sci 1993; 695: 304–6PubMedGoogle Scholar
  420. 420.
    Raves ML, Harel M, Pang YP, et al. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat Struct Biol 1997; 4: 57–63PubMedGoogle Scholar
  421. 421.
    Skolnick AA. Old Chinese herbal medicine used for fever yields possible new Alzheimer disease therapy. JAMA 1997; 277: 776PubMedGoogle Scholar
  422. 422.
    Xu S-S, Gao Z-X, Weng Z, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer’s disease. Chung Kuo Yao Li Hsueh Pao 1995; 16: 391–5PubMedGoogle Scholar
  423. 423.
    De Smet PAGM. Drugs used in non-orthodox medicine. In: Dukes MNG, Beeley L, editors. Side effects of drugs — Annual 14. Amsterdam: Elsevier, 1990: 429–51Google Scholar
  424. 424.
    Horowitz RS, Gomez H, Moore LL, et al. Jin Bu Huan toxicity in children — Colorado 1993. MMWR 1993; 42: 633–6Google Scholar
  425. 425.
    Woolf GM, Petrovic LM, Rojter SE, et al. Acute hepatitis associated with the Chinese herbal product Jin Bu Huan. Ann Intern Med 1994; 121: 729–35PubMedGoogle Scholar
  426. 426.
    Okada F. Kampo medicine, a source of drugs waiting to be exploited. Lancet 1996; 348: 5–6PubMedGoogle Scholar
  427. 427.
    Ross C. New life for old medicine. Lancet 1993; 342: 485–6PubMedGoogle Scholar
  428. 428.
    Kimura I. Immunologic aspects of Kampo medicine. Ann NY Acad Sci 1993; 685: 529–42PubMedGoogle Scholar
  429. 429.
    Kakumu S, Yoshioka K, Wakita T, et al. Effects of TJ-9 Shosaiko-to (kampo medicine) on interferon gamma and antibody production specific for hepatitis B virus antigen in patients with type B chronic hepatitis. Int J Immunopharmacol 1991; 13: 141–6PubMedGoogle Scholar
  430. 430.
    Nagai T, Yamada H. In vivo anti-influenza virus activity of Kampo (Japanese herbal) medicine ‘Sho-seiryu-to’ and its mode of action. Int J Immunopharmacol 1994; 8: 605–13Google Scholar
  431. 431.
    Takahashi S, Yoshikawa T, Naito Y, et al. Antioxidant properties of antiulcer Kampo medicines. Free Radic Res Comm 1993; 19Suppl. 1: S101–8Google Scholar
  432. 432.
    Ondrias K, Stasko A, Gergel D, et al. Formation of stable free radicals from kampo medicines TJ-9, TJ-15, TJ-23, TJ-96, TJ-114 and their antioxidant effect on low density lipoproteins. Free Radic Res Comm 1992; 16: 227–37Google Scholar
  433. 433.
    De Smet PAGM. Herbal pharmacovigilance. In: De Smet PAGM, Keller K, Hänsel R, et al., editors. Adverse effects of herbal drugs. Vol. 3. Heidelberg: Springer-Verlag, 1997: 1–13Google Scholar
  434. 434.
    Tatsuta M, Iishi H. Effect of treatment with Liu-Jun-Tang (TJ-43) and gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment Pharmacol Ther 1993; 7: 459–62PubMedGoogle Scholar
  435. 435.
    Egashira Y, Nagano H. A multicenter clinical trial of TJ-96 in patients with steroid-dependent asthma: a comparison of groups allocated by the envelope method. Ann NY Acad Sci 1993; 685: 580–3PubMedGoogle Scholar
  436. 436.
    Hirayama C, Okumura M, Tanikawa K, et al. A multicenter randomized controlled clinical trial of Syo-saiko-to in chronic active hepatitis. Gastroenterol Jpn 1989; 24: 715–9PubMedGoogle Scholar
  437. 437.
    Oka H, Yamamoto S, Kuroki T, et al. Prospective study of chemoprevention of hepatocellular carcinoma with Shosaiko-to (TJ-9). Cancer 1995; 76: 743–9PubMedGoogle Scholar
  438. 438.
    Baba S. Double-blind clinical trial of Sho-seiryu-to (TJ-19) for perennial nasal allergy. Practica Otologica 1995; 88: 389–405Google Scholar
  439. 439.
    Aslam M. Asian medicine and its practice in Britain. In: Evans WC, editor. Trease and Evans’ pharmacognosy. 14th ed. London: WB Saunders Co. Ltd, 1996: 488–504Google Scholar
  440. 440.
    Thatte UM, Dahanukar SA. Ayurveda and contemporary scientific thought. Trends in Pharmaceutical Sciences 1986; 7: 247–51Google Scholar
  441. 441.
    Vaidya AB, Antarkar VDS. New drugs from medicinal plants: opportunities and approaches. J Assoc Phys India 1994; 42: 221–8Google Scholar
  442. 442.
    Mahajani SS, Doshi VJ, Parikh KM, et al. Bioavailability of L-DOPA from HP-200 — a formulation of seed powder of Mucuna pruriens (Bak): a pharmacokinetic and pharmacodynamic study. Phytother Res 1996; 10: 254–6Google Scholar
  443. 443.
    The fifth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154–83Google Scholar
  444. 444.
    Lederle FA, Applegate WB, Grimm Jr RH. Reserpine and the medical marketplace [editorial]. Arch Intern Med 1993; 153: 705–6PubMedGoogle Scholar
  445. 445.
    Fraser HS. Reserpine: a tragic victim of myths, marketing, and fashionable prescribing. Clin Pharmacol Ther 1996; 60: 368–73PubMedGoogle Scholar
  446. 446.
    USP DI. Drug Information for the Health Care Professional. 17th ed. Vol. I. Rockville: United States Pharmacopeial Convention, Inc., 1997: 2508–11Google Scholar
  447. 447.
    Urquhart J. Correlates of variable patient compliance in drug trials: relevance in the new health care environment. Adv Drug Res 1995; 26: 237–57Google Scholar
  448. 448.
    Gugulipid. Drugs Future 1988; 13: 618–9Google Scholar
  449. 449.
    Singh RB, Niaz MA, Ghosh S. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther 1994; 8: 659–64PubMedGoogle Scholar
  450. 450.
    Thappa DM, Dogra J. Nodulocystic acne: oral gugulipid versus tetracycline. J Dermatol 1994; 21: 729–31PubMedGoogle Scholar
  451. 451.
    Nuttall FQ. Dietary fiber in the management of diabetes. Diabetes 1993; 42: 503–8PubMedGoogle Scholar
  452. 452.
    Groop PH, Aro A, Stenman S, et al. Long-term effects of guar gum in subjects with non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1993; 58: 513–8PubMedGoogle Scholar
  453. 453.
    Sesmilo G, Coves MJ, Gomis R. Guar gum in the treatment of NIDDM. Diabetes Care 1995; 18: 584–5PubMedGoogle Scholar
  454. 454.
    Bennett WG, Cerda JJ. Benefits of dietary fiber: myth or medicine? Postgrad Med 1996; 99: 153–75PubMedGoogle Scholar
  455. 455.
    Todd PA, Benfield P, Goa KL. Guar gum: a review of its pharmacological properties, and use as dietary adjunct in hypercholesterolaemia. Drugs 1990; 39: 917–28PubMedGoogle Scholar
  456. 456.
    Ma CB, Hart LL. Guar gum in hyperlipidemia. Ann Pharmacother 1990; 24: 480–1Google Scholar
  457. 457.
    Salenius J-P, Harju E, Jokela H, et al. Long term effects of guar gum on lipid metabolism after carotid endarterectomy. BMJ 1995; 310: 95–6PubMedGoogle Scholar
  458. 458.
    Morton JF. The balsam pear — an edible, medicinal and toxic plant. Econ Bot 1967; 21: 57–68Google Scholar
  459. 459.
    Aslam M, Healy MA. Hypoglycaemic properties in traditional medicines with specific reference to karela. Int Pharm J 1989; 3: 226–9Google Scholar
  460. 460.
    Baldwa VS, Bhandari CM, Pangaria A, et al. Clinical trial in patients with diabetes mellitus of an insulin-like compound obtained from plant source. Ups J Med Sci 1977; 82: 39–41PubMedGoogle Scholar
  461. 461.
    Khanna P, Jain SC, Panagariya A, et al. Hypoglycemic activity of polypeptide-p from a plant source. J Nat Prod 1981; 44: 648–55PubMedGoogle Scholar
  462. 462.
    Leatherdale BA, Panesar RK, Singh G, et al. Improvement in glucose tolerance due to Momordica charantia (karela). BMJ 1981; 282: 1823–4PubMedGoogle Scholar
  463. 463.
    Welihinda J, Karunanayake EH, Sheriff MHR, et al. Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. J Ethnopharmacol 1986; 17: 277–82PubMedGoogle Scholar
  464. 464.
    Platel K, Srinivasan K. Effect of dietary intake of freeze dried bitter gourd (Momordica charantia) in streptozotocin induced diabetic rats. Nahrung 1995; 39: 262–8PubMedGoogle Scholar
  465. 465.
    Day C, Cartwright T, Provost J, et al. Hypoglycaemic effect of Momordica charantia extracts. Planta Med 1990; 56: 426–9PubMedGoogle Scholar
  466. 466.
    Yeung HW, Li WW, Feng Z, et al. Trichosanthin, α-momorcharin and β-momorcharin: identity of abortifacient and ribosome-inactivating proteins. Int J Pept Protein Res 1988; 31: 265–8PubMedGoogle Scholar
  467. 467.
    Chan WY, Tam PPL, Yeung HW. The termination of early pregnancy in the mouse by β-momorcharin. Contraception 1984; 29: 91–100PubMedGoogle Scholar
  468. 468.
    Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single-blind trial of holy basil leaves in patients with non-insulin-dependent diabetes mellitus. Int J Clin Pharmacol Ther 1996; 34: 406–9PubMedGoogle Scholar
  469. 469.
    Venkateswaran PS, Millman I, Blumberg BS. Effects of an extract from Phyllanthus niruri on hepatitis B and woodchuck hepatitis viruses: in vitro and in vivo studies. Proc Natl Acad Sci USA 1987; 84: 274–8PubMedGoogle Scholar
  470. 470.
    Thyagarajan SP, Subramanian S, Thirunalasundari T, et al. Effect of Pyllanthus amarus on chronic carriers of hepatitis B virus. Lancet 1988; 2: 764–6PubMedGoogle Scholar
  471. 471.
    Thyagarajan SP, Jayaram S, Valliammai T, et al. Pyllanthus amarus and hepatitis B. Lancet 1990; 336: 949–50PubMedGoogle Scholar
  472. 472.
    Leelarasamee A, Trakulsomboon S, Maunwonggyathi P, et al. Failure Phyllanthus amarus to eradicate hepatitis B surface antigen from symptomless carriers. Lancet 1990: 1: 1600–1Google Scholar
  473. 473.
    Berk L, De Man RA, Schalm SW, et al. Beneficial effects og Phyllanthus amarus for chronic hepatitis B, not confirmed. J Hepatol 1991; 12: 405–6PubMedGoogle Scholar
  474. 474.
    Milne A, Hopkirk N, Lucas CR, et al. Failure of New Zealand hepatitis B carriers to respond to Phyllanthus amarus. NZ Med J 1994; 107: 243Google Scholar
  475. 475.
    Bharani A, Ganguly A, Bhargava KD. Salutary effect of Terminalia arjuna in patients with severe refractory heart failure. Int J Cardiol 1995; 49: 191–9PubMedGoogle Scholar
  476. 476.
    Dwivedi S, Chansouria JPN, Somani PN, et al. Effect of Terminalia arjuna on ischaemic heart disease. Altern Med 1989; 3: 115–22Google Scholar
  477. 477.
    Dwivedi S, Agarwal MP. Antianginal and cardioprotective effects of Terminalia arjuna, an indigenous drug, in coronary artery disease. J Assoc Phys India 1994; 42: 287–9Google Scholar
  478. 478.
    Dwivedi S, Agarwal MP. Antianginal and cardioprotective effects of Terminalia arjuna — reply from authors. J Assoc Phys India 1994; 42: 757Google Scholar
  479. 479.
    Ammon HP, Müller AB. Forskolin: from an ayurvedic remedy to a modern agent. Planta Med 1985: 473–7Google Scholar
  480. 480.
    Seamon KB, Daly JW. Forskolin: its biological and chemical properties. Adv Cyclic Nucleotide Protein Phosphorylation Res 1986; 20: 1–150PubMedGoogle Scholar
  481. 481.
    Bhat SV. Forskolin and congeners. Fortschr Chem Org Naturstoffe 1993; 62: 1–74Google Scholar
  482. 482.
    De Souza NJ. Industrial development of traditional drugs: the forskolin example: a mini-review. J Ethnopharmacol 1993; 38: 177–80PubMedGoogle Scholar
  483. 483.
    Laurenza A, Sutkowski EM, Seamon KB. Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action? Trends in Pharmaceutical Sciences 1989; 10: 442–7Google Scholar
  484. 484.
    Meyer BH, Stulting AA, Muller FO, et al. The effects of forskolin eye drops on intra-ocular pressure. S Afr Med J 1987; 71: 570–1PubMedGoogle Scholar
  485. 485.
    Erne P, Mittelholzer E, Rogg H, et al. Vasodilating agents and platelet function: intracellular free calcium concentration, cyclic nucleotides and shape-change response. J Cardiovasc Pharmacol 1986; 8Suppl. 8: S102–6PubMedGoogle Scholar
  486. 486.
    Baumann G, Felix S, Sattelberger U, et al. Cardiovascular effects of forskolin (HL 362) in patients with idiopathic congestive cardiomyopathy — a comparative study with dobutamine and sodium nitroprusside. J Cardiovasc Pharmacol 1990; 16: 93–100PubMedGoogle Scholar
  487. 487.
    Kaik G, Witte PU. Protektiver Effekt von Forskolin gegenüber Acetylcholinprovokation bei gesunden Probanden: vergleich von 2 Dosen mit Fenoterol und Placebo. Wien Med Wochenschr 1986; 136: 637–41PubMedGoogle Scholar
  488. 488.
    Bauer K, Dietersdorfer F, Sertl K, et al. Pharmacodynamic effects of inhaled dry powder formulations of fenoterol and colforsin in asthma. Clin Pharmacol Ther 1993; 53: 76–83PubMedGoogle Scholar
  489. 489.
    Mori M, Takeuchi M, Takaoka H, et al. Effect of NKH477, a new water-soluble forskolin derivative, on arterial-ventricular coupling and mechanical energy transduction in patients with left ventricular systolic dysfunction: comparison with dobutamine. J Cardiovasc Pharmacol 1994; 24: 310–6PubMedGoogle Scholar
  490. 490.
    De Souza NJ. Rohitukine and forskolin: second-generation immunomodulatory, intraocular-pressure-lowering, and cardiotonic analogues. In: Kinghorn AD, Balandrin MF, editors. Human medicinal agents from plants: ACS Symposium Series 534. Washington, DC: American Chemical Society, 1993: 331–40Google Scholar
  491. 491.
    De Smet PAGM, Rivier L. A general outlook on ethnopharmacology. J Ethnopharmacol 1989; 25: 127–38PubMedGoogle Scholar
  492. 492.
    De Smet PAGM. Drugs used in non-orthodox medicine. In: Dukes MNG, Beeley L, editors. Side effects of drugs — Annual 13. Amsterdam: Elsevier, 1989: 442–73Google Scholar
  493. 493.
    Balandrin MF, Kinghorn AD, Farnsworth NR. Plant-derived natural products in drug discovery and development: an overview. In: Kinghorn AD, Balandrin MF, editors. Human medicinal agents from plants: ACS Symposium Series 534. Washington, DC: American Chemical Society, 1993: 2–12Google Scholar
  494. 494.
    Koller WC, Silver DE, Lieberman A, et al. An algorithm for the management of Parkinson’s disease. Neurology 1994; 44Suppl. 10: S5–52Google Scholar
  495. 495.
    Drugs for Parkinson’s disease reviewed. Drug Ther Bull 1995; 33: 49–52Google Scholar
  496. 496.
    Quinn N. Drug treatment of parkinson’s disease. BMJ 1995; 310: 575–9PubMedGoogle Scholar
  497. 497.
    Corboy DL, Wagner ML, Sage JI. Apomorphine for motor fluctuations and freezing in Parkinson’s disease. Ann Pharmacotherapy 1995; 29: 282–8Google Scholar
  498. 498.
    Moerman, DE. Medicinal plants of native America. Vol. one. Ann Arbor: Univ of Michigan Museum of Anthropology, 1986: 477Google Scholar
  499. 499.
    Bauer R. Chinesische Arzneidrogen und ihr Potential für die westliche Medizin. Dtsch Apoth Ztg 1995; 140: 1929–41Google Scholar
  500. 500.
    Chan K. Progress in traditional Chinese medicine. Trends in Pharmaceutical Sciences 1995; 16: 182–7Google Scholar
  501. 501.
    Marks DR, Rapoport A, Pädia D, et al. A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache. Cephalgia 1993; 13: 114–6Google Scholar
  502. 502.
    Roth WE. An introductory study of the arts, crafts, and customs of the Guiana Indians. Annual report of the Bureau of American Ethnology to the Secretary of the Smithsonian Institution 1924; 38: 25–745Google Scholar
  503. 503.
    Wyde PR, Meyerson LR, Gilbert BE. In vitro evaluation of the antiviral activity of SP-303, an Euphorbiaceae shrub extract, against a panel of respiratory viruses. Drug Develop Res 1993; 28: 467–72Google Scholar
  504. 504.
    Gilbert BE, Wyde PR, Wilson SZ, et al. SP-303 small-particle aerosol treatment of influenza A virus infection in mice and respiratory syncytial virus infection in cotton rats. Antiviral Research 1993; 21: 37–45PubMedGoogle Scholar
  505. 505.
    Sidwell RW, Huffman JH, Moscon BJ, et al. Influenza virus-inhibitory effects of intraperitoneally and aerosol-administered SP-303, a plant flavonoid. Chemotherapy 1994; 40: 42–50PubMedGoogle Scholar
  506. 506.
    King SR, Tempesta MS. From shaman to human clinical trials: the role of industry in ethnobotany, conservation and community reciprocity. Ciba Foundation Symposium 1994; 185: 197–213PubMedGoogle Scholar
  507. 507.
    Virend heals herpes lesions [editorial]. AIDS Patient Care and STDs 1996; 10: 132Google Scholar
  508. 508.
    Spjut RW, Perdue Jr RE. Plant folklore: a tool for predicting sources of antitumor activity. Cancer Treat Rep 1976; 60: 979–85PubMedGoogle Scholar
  509. 509.
    Paclitaxel for ovarian cancer. Drug Ther Bull 1994; 32: 41–2Google Scholar
  510. 510.
    Covens A, Boucher S, Roche K, et al. Is paclitaxel and cisplatin a cost-effective first-line therapy for advanced ovarian carcinoma? Cancer 1996; 77: 2086–91PubMedGoogle Scholar
  511. 511.
    Launois R, Reboul-Marty J, Henry B, et al. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer: docetaxel versus paclitaxel versus vinorelbine. Pharmaco-Economics 1996; 10: 504–21Google Scholar
  512. 512.
    Messori A, Trippoli S, Becagli P, et al. Pharmaeoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma: a lifetime cost-effectiveness analysis. Cancer 1996; 78: 2366–73PubMedGoogle Scholar
  513. 513.
    McGuire W, Neugut AI, Arikian S, et al. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 1997; 15: 640–5PubMedGoogle Scholar
  514. 514.
    Radack K, Wyderski RJ. Conservative management of intermittent claudication. Ann Intern Med 1990; 113: 135–46PubMedGoogle Scholar
  515. 515.
    Van der Kuy A, editor. Farmacotherapeutisch Kompas 1997: uitgave van de Centrale Medisch Pharmaceutische Commissie van de Ziekenfondsraad. Amstelveen: Ziekenfondsraad, 1997Google Scholar
  516. 516.
    Bauer U. 6-month double-blind randomised clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency. Arneimittel Forschung 1984; 34: 716–20Google Scholar
  517. 517.
    Heyndrickx G, Brioen P, Van Puyvelde L. Study of Rwandese medicinal plants used in the treatment of scabies. J Ethnopharmacol 1992; 35: 259–62PubMedGoogle Scholar
  518. 518.
    Van Puyvelde L. Ontwikkeling van geneesmiddelen op basis van traditionele geneesmiddelen in Rwanda. Foliola 1995; 2: 37–62Google Scholar
  519. 519.
    Van Puyvelde L, Heyndrickx G, Brioen P, et al. Development of an anti-scabies drug from the roots of Neorautanenia mitis. Planta Med 1990; 56: 643Google Scholar
  520. 520.
    Van Puyvelde L, De Kimpe N, Mudaheranwa J-P, et al. Isolation and structural elucidation of potentially insecticidal and acaricidal isoflavone-type compounds from Neorautanenia mitis. J Nat Prod 1987; 50: 349–56Google Scholar
  521. 521.
    Van Dunkel F, Weaver D, Rusuku G, et al. Antimicrobial and insecticidal activity of the essential oil from the leaves of Tetradenia riparia [abstract]. Planta Med 1990; 56: 645Google Scholar
  522. 522.
    Van Puyvelde L, Nyirankuliza S, Panebianco R, et al. Active principles of Tetradenia riparia: I. Antimicrobial activity of 8(14), 15-sandaracopimaradiene-7α, 18-diol. J Ethnopharmacol 1986; 17: 269–75PubMedGoogle Scholar
  523. 523.
    Hari L, De Buyck LF, De Pooter HL. Naphthoquinoid pigments from Pentas longiflora. Phytochemistry 1991; 30: 1726–7Google Scholar
  524. 524.
    Conserving indigenous knowledge: integrating two systems of innovation. An independent study by the Rural Advancement Foundation International [editorial]. New York: Bureau for Policy and Programme Support, United Nations Development Programme, 1994Google Scholar
  525. 525.
    Gyllenhaal C, Farnsworth NR, editors. Special issue: intellectual property rights, naturally derived bioactive compounds and resource conservation. J Ethnopharmacol 1996; 51: 1–336Google Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  1. 1.Pharmaceutical Care UnitScientific Institute Dutch PharmacistsThe HagueThe Netherlands

Personalised recommendations